NanoViricides views options for EKC drug

1 June 2008

US firm NanoViricides says that it has signed or has in attorney-review non-disclosure agreements with major pharmaceutical companies to enable further discussions regarding its nanoviricide drug candidate against epidemic kerato-conjunctivitis (EKC). "We have already scheduled meetings to discuss the results of our recent animal studies against EKC," said the company's Eugene Seymour adding: "we have significant interest from several large pharma companies in both the USA and abroad."

The company has previously reported that it has seen rapid and significant clinical response using a nanoviricide drug candidate eye-drop treatment in animal eyes. EKC was induced by adenovirus-5 viral infection in this study. The trial is now in its final stages and the biological samples collected will be analyzed over the next several weeks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight